"Aminopyridines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Pyridines substituted in any position with an amino group. May be hydrogenated, but must retain at least one double bond.
Descriptor ID |
D000631
|
MeSH Number(s) |
D02.092.080 D03.383.725.050
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Aminopyridines".
Below are MeSH descriptors whose meaning is more specific than "Aminopyridines".
This graph shows the total number of publications written about "Aminopyridines" by people in this website by year, and whether "Aminopyridines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2000 | 1 | 0 | 1 |
2004 | 1 | 0 | 1 |
2005 | 0 | 1 | 1 |
2008 | 0 | 2 | 2 |
2009 | 3 | 0 | 3 |
2011 | 4 | 0 | 4 |
2012 | 2 | 2 | 4 |
2013 | 3 | 0 | 3 |
2014 | 3 | 2 | 5 |
2015 | 5 | 3 | 8 |
2016 | 4 | 3 | 7 |
2017 | 6 | 3 | 9 |
2018 | 10 | 0 | 10 |
2019 | 5 | 5 | 10 |
2020 | 7 | 1 | 8 |
2021 | 8 | 7 | 15 |
2022 | 1 | 6 | 7 |
2023 | 0 | 2 | 2 |
2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Aminopyridines" by people in Profiles.
-
Inhibition of CSF1R and KIT With Pexidartinib Reduces Inflammatory Signaling and Cell Viability in Endometriosis. Endocrinology. 2024 Feb 20; 165(4).
-
IDH2 mutations in acute myeloid leukemia. Leuk Lymphoma. 2023 Nov-Dec; 64(11):1733-1741.
-
Characteristics and Outcomes in Cases of US Male Patients with Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice. Adv Ther. 2023 05; 40(5):2515-2523.
-
HDAC inhibitor chidamide synergizes with venetoclax to inhibit the growth of diffuse large B-cell lymphoma via down-regulation of MYC, BCL2, and TP53 expression. J Zhejiang Univ Sci B. 2022 Aug 15; 23(8):666-681.
-
Two-pore channel blockade by phosphoinositide kinase inhibitors YM201636 and PI-103 determined by a histidine residue near pore-entrance. Commun Biol. 2022 07 23; 5(1):738.
-
Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma. Clin Cancer Res. 2022 07 15; 28(14):3002-3010.
-
Identification of cell type-specific correlations between ERK activity and cell viability upon treatment with ERK1/2 inhibitors. J Biol Chem. 2022 08; 298(8):102226.
-
Adjuvant Abemaciclib Plus Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A. JCO Oncol Pract. 2022 07; 18(7):516-519.
-
Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. Blood Cancer J. 2022 01 25; 12(1):10.
-
Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c). Blood Cancer J. 2022 01 11; 12(1):5.